Cogent Biosciences, Inc. (COGT) Operating cash flow 2017–2025
Cogent Biosciences, Inc. (COGT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$264.4MFY2025 · since FY2017: -$25.8M → -$264.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$264.4M | -27.3% |
| FY2024 | -$207.8M | -35.3% |
| FY2023 | -$153.6M | -29.5% |
| FY2022 | -$118.6M | -101.9% |
| FY2021 | -$58.8M | -63.9% |
| FY2020 | -$35.9M | +13.6% |
| FY2019 | -$41.5M | -27.8% |
| FY2018 | -$32.5M | -25.8% |
| FY2017 | -$25.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More COGT financial trends
COGT RevenueCOGT Net incomeCOGT Net marginCOGT Gross profitCOGT Gross marginCOGT Operating incomeCOGT Operating marginCOGT Free cash flowCOGT Capital expendituresCOGT Return on equityCOGT Stock buybacksCOGT Dividends paidCOGT Total assetsCOGT Total liabilitiesCOGT Shareholders’ equityCOGT overview →